| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BBRC.2005.01.139 |
| P698 | PubMed publication ID | 15721318 |
| P50 | author | Susumu Katsuma | Q91794056 |
| P2093 | author name string | Akira Hirasawa | |
| Gozoh Tsujimoto | |||
| P433 | issue | 1 | |
| P304 | page(s) | 386-390 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. | |
| P478 | volume | 329 |
| Q27301757 | A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice |
| Q38718299 | A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes |
| Q47888547 | A gut-brain axis regulating glucose metabolism mediated by bile acids and competitive fibroblast growth factor actions at the hypothalamus. |
| Q56534254 | A selective gut bacterial bile salt hydrolase alters host metabolism |
| Q36699710 | Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway |
| Q92220093 | Activation of TGR5 Partially Alleviates High Glucose-Induced Cardiomyocyte Injury by Inhibition of Inflammatory Responses and Oxidative Stress |
| Q36727325 | Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis. |
| Q41768873 | Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice |
| Q36399942 | Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells |
| Q35309093 | Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders |
| Q38172109 | Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes |
| Q41996948 | BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis |
| Q36163431 | Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass? |
| Q51294860 | Berberine attenuates high glucose-induced fibrosis by activating the G protein-coupled bile acid receptor TGR5 and repressing the S1P2/MAPK signaling pathway in glomerular mesangial cells. |
| Q94527115 | Bile Acid Receptors and Gastrointestinal Functions |
| Q36607910 | Bile Acid Receptors and Liver Cancer |
| Q47135121 | Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System |
| Q35257218 | Bile Acid signaling in liver metabolism and diseases |
| Q38364542 | Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa |
| Q34404599 | Bile acid binding resin improves metabolic control through the induction of energy expenditure |
| Q35620287 | Bile acid mediated effects on gut integrity and performance of early-weaned piglets |
| Q27002873 | Bile acid metabolism and signaling |
| Q57128767 | Bile acid metabolism and signaling in liver disease and therapy |
| Q35917864 | Bile acid metabolism and the pathogenesis of type 2 diabetes |
| Q47645986 | Bile acid metabolism in liver pathobiology |
| Q41899407 | Bile acid receptor TGR5, NADPH Oxidase NOX5-S and CREB Mediate Bile Acid-Induced DNA Damage In Barrett's Esophageal Adenocarcinoma Cells |
| Q38132058 | Bile acid receptors as targets for drug development. |
| Q36145170 | Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease |
| Q37586952 | Bile acid receptors in non-alcoholic fatty liver disease |
| Q57128781 | Bile acid receptors link nutrient sensing to metabolic regulation |
| Q33651272 | Bile acid sequestrants for lipid and glucose control |
| Q38195530 | Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. |
| Q57124605 | Bile acid signaling and bariatric surgery |
| Q28244875 | Bile acid signaling in metabolic disease and drug therapy |
| Q94475532 | Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease |
| Q39228891 | Bile acids and bariatric surgery |
| Q33610738 | Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration |
| Q37538343 | Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives |
| Q37809702 | Bile acids and their pathophysiological role in metabolic disorders |
| Q52588032 | Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. |
| Q27022441 | Bile acids as metabolic regulators |
| Q47134180 | Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. |
| Q90731281 | Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs |
| Q48042610 | Bile acids in glucose metabolism in health and disease |
| Q54242842 | Bile acids induce glucagon-like peptide 2 secretion with limited effects on intestinal adaptation in early weaned pigs. |
| Q27020976 | Bile acids, obesity, and the metabolic syndrome |
| Q26796318 | Bile acids: emerging role in management of liver diseases |
| Q24658139 | Bile acids: regulation of synthesis |
| Q34559902 | Bile alcohols function as the ligands of membrane-type bile acid-activated G protein-coupled receptor |
| Q37638724 | Bile salt receptor TGR5 is highly expressed in esophageal adenocarcinoma and precancerous lesions with significantly worse overall survival and gender differences |
| Q84981964 | Bile salts and obesity |
| Q37737870 | Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? |
| Q41978789 | Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1. |
| Q51245210 | CD36 modulates fasting and preabsorptive hormone and bile acid levels. |
| Q42477615 | COMPARATIVE GUT PHYSIOLOGY SYMPOSIUM: Comparative physiology of glucagon-like peptide-2: Implications and applications for production and health of ruminants |
| Q33828259 | Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model |
| Q24635181 | Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis |
| Q47163551 | Chenodeoxycholic acid attenuates high-fat diet-induced obesity and hyperglycemia via the G protein-coupled bile acid receptor 1 and proliferator-activated receptor γ pathway |
| Q38590747 | Cholestatic liver (dys)function during sepsis and other critical illnesses |
| Q41649308 | Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis |
| Q36423113 | Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP. |
| Q38957548 | Clinical relevance of the bile acid receptor TGR5 in metabolism. |
| Q46352618 | Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. |
| Q43203779 | Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. |
| Q35898255 | Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function |
| Q33854022 | Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence |
| Q35591749 | Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass |
| Q44915348 | Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes |
| Q92666284 | Correlation between 12α-hydroxylated bile acids and insulin secretion during glucose tolerance tests in rats fed a high-fat and high-sucrose diet |
| Q60924100 | Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis |
| Q30382902 | Daily Eating Patterns and Their Impact on Health and Disease. |
| Q38986670 | Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators |
| Q50916799 | Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists. |
| Q36414100 | Determinants of post-prandial plasma bile acid kinetics in human volunteers |
| Q95280006 | Dietary supplementation with Lactobacillus plantarum modified gut microbiota, bile acid profile and glucose homeostasis in weaning piglets |
| Q40012754 | Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. |
| Q30277979 | Differences in Weight Loss and Gut Hormones: Rouen-Y Gastric Bypass and Sleeve Gastrectomy Surgery |
| Q92670131 | Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model |
| Q38081417 | Digestive physiology of the pig symposium: potential applications of knowledge of gut chemosensing in pig production |
| Q38073233 | Digestive physiology of the pig symposium: secretion of gastrointestinal hormones and eating control |
| Q42053775 | Dipeptidyl peptidase IV inhibition potentiates amino acid- and bile acid-induced bicarbonate secretion in rat duodenum |
| Q64121752 | Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1 |
| Q53493506 | Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes. |
| Q36473140 | Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist |
| Q58572799 | Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1 |
| Q57111541 | Duodenal chemosensing |
| Q57107999 | Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids |
| Q35208562 | Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats |
| Q51364519 | Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. |
| Q34475476 | Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials |
| Q39989391 | Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion |
| Q57154246 | Effect of supplementary calcium phosphate on plasma gastrointestinal hormones in a double-blind, placebo-controlled, cross-over human study |
| Q51368980 | Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. |
| Q53688580 | Effects of Diet on Bile Acid Metabolism and Insulin Resistance in Type 2 Diabetic Rats after Roux-en-Y Gastric Bypass. |
| Q37114043 | Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus |
| Q57099276 | Effects of dietary pectin on the profile and transport of intestinal bile acids in young pigs |
| Q43280966 | Effects of vitamin E on serum enzymes and electrolytes in hypercholesterolemia |
| Q35205214 | Emerging science of the human microbiome |
| Q39390970 | Endocrine Function after Bariatric Surgery |
| Q37287593 | Endocrine and paracrine role of bile acids |
| Q34545426 | Endocrine functions of bile acids |
| Q38067511 | Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease |
| Q40171230 | Engineered enteroendocrine cells secrete insulin in response to glucose and reverse hyperglycemia in diabetic mice. |
| Q58147741 | Essential roles of bile acid receptors FXR and TGR5 as metabolic regulators |
| Q37995315 | Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes |
| Q39726655 | Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. |
| Q36593470 | Expression of bile acid receptor TGR5 in gastric adenocarcinoma |
| Q36573090 | FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes |
| Q35063271 | Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity |
| Q51016869 | Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. |
| Q57145576 | Fatty acid-binding protein 5 regulates diet-induced obesity via GIP secretion from enteroendocrine K cells in response to fat ingestion |
| Q30576325 | Feeding-dependent activation of enteric cells and sensory neurons by lymphatic fluid: evidence for a neurolymphocrine system. |
| Q38095825 | From gut changes to type 2 diabetes remission after gastric bypass surgeries |
| Q49166800 | Fructo-oligosaccharides and glucose homeostasis: a systematic review and meta-analysis in animal models. |
| Q36849190 | G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes |
| Q51282593 | G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. |
| Q37635259 | GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation |
| Q35581251 | Gastrointestinal hormones and bariatric surgery-induced weight loss |
| Q57109437 | Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21 |
| Q90260620 | Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function |
| Q89442824 | Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function |
| Q34890796 | Glucose sensing in L cells: a primary cell study |
| Q90503100 | Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures |
| Q36699764 | Gustducin couples fatty acid receptors to GLP-1 release in colon |
| Q57107261 | Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer |
| Q46557331 | Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice |
| Q37990142 | Gut feelings about diabetes |
| Q39230899 | Gut microbiota functions: metabolism of nutrients and other food components |
| Q24682766 | Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 |
| Q38861231 | HORSE SPECIES SYMPOSIUM: Canine intestinal microbiology and metagenomics: From phylogeny to function |
| Q34775887 | Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats. |
| Q39780596 | Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists |
| Q36077699 | Importance of Large Intestine in Regulating Bile Acids and Glucagon-Like Peptide-1 in Germ-Free Mice. |
| Q42931484 | Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism |
| Q92619440 | Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases |
| Q36629984 | Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects |
| Q36964866 | Incretin-based therapies in type 2 diabetes mellitus |
| Q51367888 | Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. |
| Q92106425 | Intestinal Absorption of Bile Acids in Health and Disease |
| Q39156532 | Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation |
| Q37034939 | Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect |
| Q52682856 | Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. |
| Q50522015 | Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice. |
| Q38855893 | Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. |
| Q35928810 | Is There a Place for Dietary Fiber Supplements in Weight Management? |
| Q38623207 | Is there any interplay between incretins and bile acids? What is the role of bariatric surgery? |
| Q39747808 | Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). |
| Q61797279 | Lactobacillus mucosae DPC 6426 as a bile-modifying and immunomodulatory microbe |
| Q90429528 | Leveraging the Gut to Treat Metabolic Disease |
| Q36368928 | Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor. |
| Q33920932 | Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose |
| Q39971991 | Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants |
| Q26780440 | Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review |
| Q39090294 | Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids |
| Q49237889 | Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells |
| Q26770832 | Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors |
| Q91919560 | Metabolic Effects of Bile Acids: Potential Role in Bariatric Surgery |
| Q37922651 | Metabolic surgery-principles and current concepts |
| Q28072517 | Microbial regulation of GLP-1 and L-cell biology |
| Q58738024 | Models and Tools for Studying Enteroendocrine Cells |
| Q39515338 | Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion |
| Q37667168 | Molecular mechanisms underlying nutrient-stimulated incretin secretion |
| Q38194905 | Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract |
| Q28547520 | Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice |
| Q26748613 | Novel bile acid therapeutics for the treatment of chronic liver diseases |
| Q34193332 | Nutritional regulation of bile acid metabolism is associated with improved pathological characteristics of the metabolic syndrome |
| Q37322912 | Nutritional regulation of glucagon-like peptide-1 secretion |
| Q37325663 | OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition |
| Q57136131 | Obesity diabetes and the role of bile acids in metabolism |
| Q35054892 | Obesity surgery and gut-brain communication |
| Q90614479 | Oxysterols of helminth parasites and pathogenesis of foodborne hepatic trematodiasis caused by Opisthorchis and Fasciola species |
| Q38049636 | Patented TGR5 modulators: a review (2006 - present). |
| Q38798961 | Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells. |
| Q60047622 | Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome |
| Q26799380 | Pharmacology and physiology of gastrointestinal enteroendocrine cells |
| Q38965089 | Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution? |
| Q35760279 | Physiology of incretins in health and disease |
| Q27027920 | Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease |
| Q36843966 | Pleiotropic roles of bile acids in metabolism |
| Q38364477 | Possible abilities of dietary factors to prevent and treat diabetes via the stimulation of glucagon-like peptide-1 secretion |
| Q42518451 | Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients |
| Q48177243 | Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. |
| Q37940632 | Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants |
| Q94475534 | Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model |
| Q50005567 | Proceedings of the 2017 ASPEN Research Workshop-Gastric Bypass: Role of the Gut. |
| Q26830947 | Recent advances in gut nutrient chemosensing |
| Q44964426 | Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers |
| Q42846334 | Redefining the TGR5 triterpenoid binding pocket at the C-3 position |
| Q93140198 | Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases |
| Q91842898 | Regulation of bile acid receptor activity☆ |
| Q34441486 | Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S. |
| Q49569061 | Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites |
| Q36503839 | Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease |
| Q35742169 | Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids |
| Q42255441 | Role of Bile Acid-Regulated Nuclear Receptor FXR and G Protein-Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease) |
| Q90340663 | Role of CRTC2 in Metabolic Homeostasis: Key Regulator of Whole-Body Energy Metabolism? |
| Q39772570 | Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma |
| Q26738976 | Role of bile acids in the regulation of the metabolic pathways |
| Q36497654 | Role of nuclear receptors in lipid dysfunction and obesity-related diseases. |
| Q42087161 | Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells |
| Q34146701 | Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity |
| Q33663484 | Safety and efficacy of colesevelam HCl in the treatment of elderly patients |
| Q39816226 | Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes |
| Q34763466 | Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers |
| Q64107796 | Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer |
| Q57297434 | Secondary Unconjugated Bile Acids Induce Hepatic Stellate Cell Activation |
| Q37121652 | Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial |
| Q36381636 | Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism |
| Q37309061 | Serum biochemical changes in rabbits on a regular diet with and without flax lignan complex following a high-cholesterol diet |
| Q87842301 | Signalling from the periphery to the brain that regulates energy homeostasis |
| Q37333508 | Soaping up type 2 diabetes with bile acids?: the link between glucose and bile acid metabolism in humans tightens: quality matters! |
| Q35703890 | Specific inhibition of bile acid transport alters plasma lipids and GLP-1 |
| Q38541491 | Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application |
| Q26765259 | Stimulation of incretin secreting cells |
| Q34162283 | Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases |
| Q36929467 | Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release |
| Q30499029 | Systemic gut microbial modulation of bile acid metabolism in host tissue compartments |
| Q57106799 | TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice |
| Q34094979 | TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading |
| Q54966559 | TGR5 expression in normal kidney and renal neoplasms. |
| Q38197305 | TGR5 in inflammation and cardiovascular disease |
| Q38831400 | TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro |
| Q35996467 | TGR5 potentiates GLP-1 secretion in response to anionic exchange resins |
| Q35145474 | TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation |
| Q37892289 | TGR5 sequence variation in primary sclerosing cholangitis |
| Q37531608 | TGR5, Not Only a Metabolic Regulator |
| Q39805262 | TGR5-mediated bile acid sensing controls glucose homeostasis |
| Q35094206 | TGR5: a novel target for weight maintenance and glucose metabolism |
| Q37414989 | TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity |
| Q55363824 | Takeda G Protein-Coupled Receptor 5-Mechanistic Target of Rapamycin Complex 1 Signaling Contributes to the Increment of Glucagon-Like Peptide-1 Production after Roux-en-Y Gastric Bypass. |
| Q64999554 | Targeted metabolomics study of serum bile acid profile in patients with end-stage renal disease undergoing hemodialysis. |
| Q37231731 | Targeting bile-acid signalling for metabolic diseases |
| Q26738730 | Targeting the gastrointestinal tract to treat type 2 diabetes |
| Q35577851 | Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. |
| Q38913696 | The Contributing Role of Bile Acids to Metabolic Improvements After Obesity and Metabolic Surgery |
| Q28290420 | The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells |
| Q48143632 | The Gastrointestinal Tract as an Integrator of Mechanical and Hormonal Response to Nutrient Ingestion |
| Q50080451 | The Role of GLP-1 in the Metabolic Success of Bariatric Surgery |
| Q36733406 | The TGR5 receptor mediates bile acid-induced itch and analgesia |
| Q36832832 | The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation |
| Q38115636 | The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. |
| Q35082232 | The bile acid membrane receptor TGR5: a valuable metabolic target |
| Q28590901 | The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis |
| Q37641553 | The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. |
| Q37095372 | The bile acid receptor TGR5 does not interact with β-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. |
| Q58447913 | The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model |
| Q36720538 | The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes |
| Q42774163 | The effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on dextran sulfate sodium-induced colitis in mice |
| Q57116409 | The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice |
| Q35987618 | The gut microbiota and metabolic disease: current understanding and future perspectives |
| Q38183448 | The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. |
| Q36296633 | The impact of Roux-en-Y gastric bypass surgery on normal metabolism in a porcine model |
| Q38861610 | The incretin hormone GLP-1 and mechanisms underlying its secretion |
| Q38659340 | The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids |
| Q42715520 | The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice |
| Q42363893 | The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance |
| Q24629879 | The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control |
| Q99564753 | The triterpenoid sapogenin (2α-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling |
| Q34714107 | Tissue-specific function of farnesoid X receptor in liver and intestine |
| Q36093376 | Uncoupling protein 2 regulates glucagon-like peptide-1 secretion in L-cells |
| Q35148954 | Urine bile acids relate to glucose control in patients with type 2 diabetes mellitus and a body mass index below 30 kg/m2 |
| Q51731208 | Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study. |
| Q37878588 | Using the lymphatics to study nutrient absorption and the secretion of gastrointestinal hormones |
| Q43125212 | Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor |
| Q57108626 | Weight-Independent Mechanisms of Glucose Control After Roux-en-Y Gastric Bypass |
| Q48333609 | Zizyphin modulates calcium signalling in human taste bud cells and fat taste perception in the mouse |
Search more.